Straits Times Index
3,190.71 -34.64 (-1.07%) S&P 500
3,923.68 -165.17 (-4.04%) Dow
31,490.07 -1,164.52 (-3.57%) Nasdaq
11,418.15 -566.37 (-4.73%) BTC-USD
29,006.29 -926.51 (-3.10%) CMC Crypto 200
644.74 -25.94 (-3.87%)
Nuvation Bio Inc. (NUVB)
After hours:
| Previous close | 4.2700 |
| Open | 4.1500 |
| Bid | 3.3300 x 1300 |
| Ask | 5.8500 x 1200 |
| Day's range | 4.0200 - 4.2000 |
| 52-week range | 3.5850 - 15.2300 |
| Volume | |
| Avg. volume | 913,629 |
| Market cap | 883.422M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4390 |
| Earnings date | 10 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.67 |
- Business Wire
Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
NEW YORK, May 09, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2022, and provided a business update.
- Business Wire
Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
NEW YORK, February 28, 2022--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.
- Zacks
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.
